LONDON, June 16, 2015 (GLOBE NEWSWIRE) -- From 19 th to 23 rd June, Ekso Bionics Holdings , Inc., a robotic exoskeleton company, is showcasing their Ekso Bionics robotic exoskeleton for gait therapy at the 9 th world congress of the International Society of Physical and Rehabilitation Medicine ( ISPRM 2015 ) in Berlin. At their booth, D6, Ekso Bionics experts will be on hand to discuss new FES integration, clinical applications of their exoskeleton and demonstrate the benefits of assisted gait training for patients with various levels of paralyses and hemiparesis.
The ISPRM world congress, hosted this year by the German and Austrian Societies of Physical Medicine and Rehabilitation (DGPMR & ÖGPMR), is a global meeting point for more than 3,000 international experts in the fields of physical medical, science and research. The congress offers participants a large spectrum of symposia, hands-on-workshops and seminars to learn about the latest developments in the area of physical medicine and rehabilitation.
The Ekso Bionics robotic exoskeleton is a comprehensive gait therapy tool, which provides an unparalleled rehabilitation experience for patients and therapists alike. Interactive software provides adaptive amounts of power to either side of the body and supports a broad spectrum of patients in being actively engaged in their rehabilitation. Suitable for patients with various levels of paralysis or hemiparesis due to neurological conditions such as spinal cord injury or stroke, the suit can be used in both acute and chronic gait rehabilitation. In Germany there are already nine clinics and rehabilitation centers offering Ekso Bionics assisted therapy.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com
Company Information
In addition to announcing material financial and other information about the company through press releases, SEC filings and public conference calls and webcasts, we also intend to use our investor relations website as a means of disclosing information about the company, its products and other matters and for complying with our disclosure obligations under Regulation FD. The company's investor relations website is located at ir.eksobionics.com .
Facebook: https://www.facebook.com/EksoBionicsEurope
Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K/A filed on March 31, 2014 and the Company's latest Form 10-Q filed on August 8, 2014. The Company does not undertake to update these forward-looking statements.
Press Contact: Ekso Bionics Marcus Nielsen, Marketing Manager EMEA, Tel. +49 89 5506 7774 email: MNielsen@eksobionics.com web: www.eksobionics.com < http://www.eksobionics.com >
UK PR: Otto PR for Ekso Bionics Shaun Wootton phone: 07796 338360 email: shaun@ottopr.co.uk
